Skip to content
IOL Chemicals & Pharmaceuticals logo

IOL Chemicals & Pharmaceuticals

IOLCP NSE
₹183.77 +9.39 (+5.38%)
P/E
32.07
View as Markdown
MCP
Close 4 Nov 2026 ₹183.77 +93.18 +103% 1Y
Start ₹90.59

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
11.30%
Debt to Equity
0.08
EPS (TTM)
₹5.73
Book Value
₹65.60
Market Cap
—
P/E (TTM)
32.07
P/B
2.80
ROE
8.42%
Dividend Yield
0.57%
EBITDA
₹290 Cr
52W High
₹224.00
52W Low
₹67.19
Day Range
₹169.30 – ₹185.50
Volume
18,51,032

Peer Comparison

Healthcare › Pharmaceuticals

IOL Chemicals & Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
IOL Chemicals & Pharmaceuticals (this company)
₹183.7732.07₹5,219 Cr2.800.57%8.42%11.30%₹2,524 Cr₹168 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.58%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

63 Good

Data confidence 100/100

Category scores

Quality
50
Average
Returns, margins, earnings quality 22% weight
Valuation
70
Strong
Cheap vs sector & own history 24% weight
Growth
56
Good
Sales & profit trajectory 9% weight
Financial Health
60
Good
Solvency, leverage, coverage 9% weight
Momentum
91
Strong
Trend strength, vol-adjusted 12% weight
Ownership
64
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 22.1%

Weaknesses

3
  • Stock is trading at 2.99 times its book value
  • The company has delivered a poor sales growth of 3.35% over past five years.
  • Company has a low return on equity of 7.74% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish766
OscillatorsBearish360
Moving AveragesStrong Bullish406

Key readings

RSI (14)
48.39
Neutral
MACD (12,26,9)
−4.81
Bearish
SMA (50)
193.73
Bearish
SMA (200)
130.56
Bullish

As of

Analyst Rating

Based on 1 analysts
BUY100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

As of

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+14.86%
5Y+3.35%
3Y+1.51%
1Y+11.54%
TTM+18.51%

Net profit

Net profit growth by window
10YTurned to profit
5Y−20.88%
3Y−0.48%
1Y+36.63%
TTM+58.49%

Operating cash flow

Operating cash flow growth by window
10Y+28.09%
5Y−10.85%
3Y+20.27%
1Y+19.55%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+2.85 pp
5Y−18.46 pp
3Y+1.40 pp
1Y+1.92 pp
TTM+2.28 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹711 Cr
Mar 2018₹983 Cr
Mar 2019₹1,685 Cr
Mar 2020₹1,894 Cr
Mar 2021₹1,967 Cr
Mar 2022₹2,184 Cr
Mar 2023₹2,217 Cr
Mar 2024₹2,133 Cr
Mar 2025₹2,079 Cr
Mar 2026₹2,319 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹5.00 Cr
Mar 2018₹28.00 Cr
Mar 2019₹237 Cr
Mar 2020₹361 Cr
Mar 2021₹445 Cr
Mar 2022₹166 Cr
Mar 2023₹140 Cr
Mar 2024₹135 Cr
Mar 2025₹101 Cr
Mar 2026₹138 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹365 Cr +25.6% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk medium

IOL Chemicals & Pharmaceuticals trades at a market cap of ₹4,300 Cr with a PE of 30.5x and near-zero debt. The company has seen a sharp TTM profit recovery of 44% but carries a weak 5-year sales CAGR of just 3% and a subdued 3-year ROE of 8%.

Bull Case 8
  • Company is almost debt-free, providing financial flexibility and lower interest burden
  • TTM profit growth of 44% signals a meaningful earnings recovery after years of decline
  • Promoter holding increased by 4.86% in the last quarter, indicating insider confidence
  • Stock has delivered 53% returns over the past 1 year, reflecting strong momentum
  • 10-year compounded profit growth of 19% demonstrates long-term earnings capability
  • Healthy dividend payout of 22.1% shows commitment to returning capital to shareholders
  • 10-year sales CAGR of 15% indicates the company scaled well over the longer term
  • TTM sales growth of 12% suggests demand recovery after a sluggish 3-year period
Bear Case 8
  • 5-year compounded profit growth is -20%, indicating a prolonged earnings downcycle
  • 5-year sales CAGR of only 3% reflects persistently weak topline growth
  • 3-year ROE of just 8% is well below what quality pharma/chemical companies typically deliver
  • PE of 30.5x is expensive relative to the low single-digit 3-year sales CAGR of 2%
  • 3-year compounded profit growth of only 1% shows the recovery is very recent and unproven
  • Last year ROE of 8% and 3-year ROE of 8% show no improvement in capital efficiency
  • 5-year stock CAGR of just 2% suggests the market rewarded shareholders poorly over a medium-term horizon
  • Dividend yield of 0.7% offers limited income cushion at current valuations

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: IOL Chemicals experienced a contained fire incident at one manufacturing unit with minimal impact—no injuries, no major property damage, and a short 8–10 day suspension limited to a single unit. The event is operationally insignificant given normal functioning across remaining facilities, and the outlook remains unchanged pending restoration completion.

Neutral 1
  • Minor fire at Minoxidil unit Jun 11

    A minor fire at Unit-9B in Barnala on June 9, 2026 has suspended Minoxidil operations for 8–10 days. No injuries or significant property damage reported; all other units operating normally.

Quarterly Results

₹ Cr
IOLCP quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
563
545
520
504
502
526
523
528
552
568
580
619
756
795
Expenses
490
481
476
454
452
484
476
465
490
510
523
527
653
686
Operating Profit
73
64
44
50
51
42
47
63
62
57
57
93
104
109
OPM %
13%
12%
9%
10%
10%
8%
9%
12%
11%
10%
10%
15%
14%
14%
Other Income
7
7
8
8
7
6
4
5
7
7
−6
2
8
6
Interest
4
4
4
3
2
4
4
4
4
3
4
3
4
5
Depreciation
14
16
16
16
17
18
19
19
20
20
20
20
21
22
PBT
62
51
32
38
39
26
28
45
46
41
28
71
87
87
Tax %
25%
26%
28%
25%
24%
26%
26%
30%
25%
26%
25%
25%
26%
25%
Net Profit
46
38
23
28
30
19
21
32
34
30
21
53
64
65
EPS (₹)
1.57
1.29
0.79
0.96
1.01
0.65
0.7
1.08
1.16
1.02
0.7
1.81
2.2
—

Sep 2026: from the results filed on 30 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
IOLCP profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
385
580
711
983
1,685
1,894
1,967
2,184
2,217
2,133
2,079
2,319
2,524
Expenses
373
529
608
863
1,276
1,321
1,375
1,927
1,990
1,901
1,877
2,049
2,213
Operating Profit
11
51
102
120
410
574
592
257
227
232
202
270
310
OPM %
2.9%
9%
14%
12%
24%
30%
30%
12%
10%
11%
10%
12%
12%
Other Income
1
1
1
6
10
16
24
17
25
30
22
9
11
Interest
59
61
68
64
51
21
6
8
16
16
15
15
14
Depreciation
29
30
30
30
32
36
39
43
46
63
72
80
82
PBT
−75
−39
6
31
336
533
571
223
189
183
138
184
226
Tax %
−12%
4%
21%
12%
30%
32%
22%
26%
26%
26%
27%
25%
—
Net Profit
−67
−40
5
28
237
361
445
166
140
135
101
138
168
EPS (₹)
−2.8
−1.42
0.17
0.99
8.32
12.7
15.15
5.64
4.77
4.61
3.44
4.69
5.73
Div. Payout %
0%
0%
0%
0%
0%
5%
8%
14%
17%
22%
23%
21%
—

Balance Sheet

₹ Cr
IOLCP balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
48
56
56
56
57
57
59
59
59
59
59
59
Reserves
160
129
132
160
417
757
1,202
1,332
1,448
1,553
1,629
1,740
Borrowings
400
453
447
422
284
59
3
44
80
33
117
135
Other Liabilities
94
135
182
214
184
297
347
526
434
600
577
653
Total Liabilities
702
772
817
852
942
1,170
1,610
1,960
2,021
2,244
2,382
2,587
Fixed Assets
403
400
374
406
412
469
512
561
751
933
1,170
1,181
CWIP
4
4
21
7
27
19
48
105
90
101
22
96
Investments
0
0
0
0
0
0
1
2
20
21
21
21
Other Assets
295
369
422
439
503
682
1,048
1,292
1,159
1,190
1,168
1,289
Total Assets
702
772
817
852
942
1,170
1,610
1,960
2,021
2,244
2,382
2,587

Cash Flow

₹ Cr
IOLCP cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−47
18
83
120
273
471
380
91
123
290
179
214
Investing
−5
−27
−23
−50
−63
−184
−317
−121
−119
−191
−154
−198
Financing
50
9
−60
−70
−197
−272
−58
−2
−4
−92
46
−29
Net Cash Flow
−2
0
1
−1
13
15
4
−31
0
7
70
−13
Free Cash Flow
−53
−9
61
71
213
391
272
−60
−86
18
−34
44
CFO/EBITDA
−413
34
82
105
83
102
88
60
75
144
97
93

Ratios

IOLCP financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
31
55
58
54
43
52
56
79
83
81
90
95
Inventory Days
279
201
201
109
66
64
98
95
77
111
95
91
Days Payable
92
102
115
83
42
62
79
95
74
123
112
118
Cash Conversion Cycle
218
154
144
80
67
55
74
79
86
69
73
68
Working Capital Days
59
39
36
23
43
46
66
71
72
71
58
53
ROCE %
−3%
4%
12%
15%
56%
68%
54%
18%
14%
12%
9%
11%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view IOL Chemicals & Pharmaceuticals insights

76 extracted metrics across FY07–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 62.28%
  • Public 25.88%
  • FIIs 7.25%
  • Others 4.29%
  • DIIs 0.30%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about IOL Chemicals & Pharmaceuticals

What does IOL Chemicals & Pharmaceuticals Ltd do?
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market. It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.
Where is IOL Chemicals & Pharmaceuticals Ltd (IOLCP) listed?
IOL Chemicals & Pharmaceuticals Ltd trades as IOLCP on the NSE and under code 524164 on the BSE.
Which sector does IOL Chemicals & Pharmaceuticals Ltd belong to?
IOL Chemicals & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of IOL Chemicals & Pharmaceuticals Ltd?
IOL Chemicals & Pharmaceuticals Ltd trades at a PE ratio of 32.07 as of 4 Nov 2026, on earnings per share of ₹5.73, against a book value of ₹65.6 per share.
What is the 52-week high and low of IOL Chemicals & Pharmaceuticals Ltd?
Over the last 52 weeks IOL Chemicals & Pharmaceuticals Ltd has traded between ₹67.19 and ₹224 as of 4 Nov 2026.
Does IOL Chemicals & Pharmaceuticals Ltd pay dividends?
IOL Chemicals & Pharmaceuticals Ltd has a dividend yield of 0.57%.
What is the Return on Equity (ROE) of IOL Chemicals & Pharmaceuticals Ltd?
IOL Chemicals & Pharmaceuticals Ltd reported a return on equity of 8.42%. Its debt-to-equity ratio is 0.08.

Company Information

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market. It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.

Website iolcp.com
Listed 8 Nov 2010
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/IOLCP.md for IOL Chemicals & Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month